Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 11:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 565 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CT Scans Clear all

Conditions: Lung Neoplasm
Interventions: Not listed
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Coronary Artery Disease (CAD)
Interventions: Not listed
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions: Computed Tomography, Fluorine F 18 DCFPyL, Positron Emission Tomography, Radiation Therapy; Procedure · Other · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Kidney Disease
Interventions: Blood work; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Patellar (or Kneecap) Instability and Mal-alignment
Interventions: Not listed
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 16 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Amherst, New York • Orchard Park, New York

Conditions: Lung Cancer Screening
Interventions: Low Dose CT imaging, blood draws, screening questionnaire; Diagnostic Test · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more

Conditions: Shoulder Arthroplasty
Interventions: A low-dose CT scan of the shoulder; Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cystic Fibrosis
Interventions: Magnetic resonance relaxometry, Magnetic resonance spectroscopy, Blood Draw, DXA, pQCT; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 13 Years to 20 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Sarcoma, Recurrent Sarcoma, Sarcoma
Interventions: Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG; Procedure · Drug · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cystic Fibrosis
Interventions: Active Treatment Group 7% Hypertonic Saline, Control Group 0.9% Isotonic Saline; Drug
Lead sponsor: University of Washington, the Collaborative Health Studies Coordinating Center; Other
Eligibility: 3 Years to 5 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 7
States / cities: Aurora, Colorado • Indianapolis, Indiana • St Louis, Missouri + 4 more

Conditions: Asthma, Pulmonary Function, Wheezing, In Utero Nicotine
Interventions: No active intervention in this protocol (previously randomized to Vitamin C), No active intervention in this protocol (previously randomized to Placebo); Dietary Supplement · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 6 Years to 16 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Indianapolis, Indiana • Portland, Oregon

Conditions: Coronary Disease
Interventions: Not listed
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Immune Reconstitution Inflammatory Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Cancer, Non Small Cell
Interventions: CT Scan; Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
Interventions: Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Stereotactic Body Radiation Therapy; Device · Other · Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions: Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography; Procedure · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lymphangioleiomyomatosis
Interventions: Everolimus; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Boston, Massachusetts • Cincinnati, Ohio

Conditions: Graft Versus Host Disease
Interventions: [18F]F-Ara-G; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Solid Tumor
Interventions: Proton SBRT; Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Renal Cancer
Interventions: 124IcG250; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Bone Metastases, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: magnetic resonance imaging, fluorine F 18 sodium fluoride, positron emission tomography, computed tomography, technetium Tc 99m methylene diphosphonate, laboratory biomarker analysis; Procedure · Radiation · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral Artery Disease, Diabetes Mellitus, Chronic Limb-Threatening Ischemia
Interventions: SPECT/CT perfusion imaging, PET/CT perfusion imaging; Diagnostic Test
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: computed tomography; Procedure
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Melanoma
Interventions: Bempegaldesleukin (NKTR-214), Nivolumab, ⁸⁹Zr-Df-IAB22M2C; Biological · Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Duarte, California • Portland, Oregon • Philadelphia, Pennsylvania

Search by objective public record fields.

Correlation of X-ray and Pathology With Needle Biopsy of Lung Tumors

Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care

Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer

Comparative Investigation of Intravenously Administered Omnipaque and Isovue: Effects on Serum Creatinine Concentration in Outpatients

CT Analysis of the Patellofemoral Joint in Patients Having Knee Surgery

A Study of Lung Cancer Screening in People With Unexplained Weight Loss

Prospective Low Dose CT for Total Shoulder Arthroplasty/Reverse Shoulder Arthroplasty

Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis

68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

Saline Hypertonic in Preschoolers + CT

Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up

Cardiac Computed Tomography In the Management of Patients With indeterminAte or inConclusive Stress Tests

PET Imaging and Lymph Node Assessment of IRIS in People With AIDS

Assess the Variability of Uni-Dimensional, Bi-Dimensional, and Volumetric CT Scan Measurement of Non-Small Cell Lung Cancer Tumors

Dynamic Perfusion Computed Tomography in Patients With Localized Non-small Cell Lung Cancer

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Detection of Graft Versus Host Disease With [18F]F-AraG

Online Proton Adaptive Radiotherapy

Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma

Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer

Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease

Computed Tomography in Detecting Movement of the Esophagus in Patients Undergoing Radiation Therapy to the Chest

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab